Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,359 stopped studies mapped to Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,359 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02378922 | Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated… | Phase 1 | withdrawn | Mar 4, 2015 | Fred Hutchinson Cancer Center | Administratively closed prior to subject enrollment | Enrollment / accrual |
| NCT02061449 | Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma | Phase 1 | terminated | Feb 12, 2014 | NYU Langone Health | Low Accrual | Enrollment / accrual |
| NCT02683395 | A Study of PLX51107 in Advanced Malignancies | Phase 1 | terminated | Feb 17, 2016 | Plexxikon | Business Decision | Sponsor / business decision |
| NCT01479582 | Providing Access to Cord Blood Units for Transplants | Phase 2 | withdrawn | Nov 24, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02454270 | A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory… | Phase 1 | terminated | May 27, 2015 | Janssen Research & Development, LLC | Recent advances in the treatment of B cell malignancies resulting in new treatments being approved… | Other (stated, no rule matched) |
| NCT01470131 | A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or… | Phase 3 | terminated | Nov 11, 2011 | AB Science | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT02556463 | A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With… | Phase 1 | terminated | Sep 22, 2015 | MedImmune LLC | Company strategy | Sponsor / business decision |
| NCT03349346 | Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and… | Phase 1 | withdrawn | Nov 21, 2017 | Gilead Sciences | The European Medical Agency granted a Paediatric Investigational Product-specific waiver on the… | Other (stated, no rule matched) |
| NCT01374217 | Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in… | Phase 2 | terminated | Jun 15, 2011 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | early stopping rule | Other (stated, no rule matched) |
| NCT03438344 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications… | Phase 2 | withdrawn | Feb 19, 2018 | City of Hope Medical Center | PI Withdrawal | Other (stated, no rule matched) |
| NCT02343666 | HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With… | Phase 1 | withdrawn | Jan 22, 2015 | Fred Hutchinson Cancer Center | Administrative closure prior to any enrollments | Enrollment / accrual |
| NCT01203930 | A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL | Phase 2 | terminated | Sep 17, 2010 | Gilead Sciences | not stated | Not stated |
| NCT01732913 | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously…(Yosemite) | Phase 3 | terminated | Nov 26, 2012 | Gilead Sciences | not stated | Not stated |
| NCT01732926 | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and…(Bridalveil) | Phase 3 | terminated | Nov 26, 2012 | Gilead Sciences | not stated | Not stated |
| NCT03120000 | PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System… | Phase 2 | withdrawn | Apr 19, 2017 | PIQUR Therapeutics AG | Withdrawn | Other (stated, no rule matched) |
| NCT02538926 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin… | Phase 2 | withdrawn | Sep 2, 2015 | University of Washington | Drugs unavailable | Other (stated, no rule matched) |
| NCT00038883 | Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies | N/A | terminated | Jun 7, 2002 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT02376933 | Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer | N/A | terminated | Mar 3, 2015 | University of Arizona | PI left the department; protocol transfer did not take place. | Investigator |
| NCT00038779 | Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure… | N/A | terminated | Jun 7, 2002 | M.D. Anderson Cancer Center | Lack of Accrual | Enrollment / accrual |
| NCT00790842 | Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple…(PrE1003) | Phase 1 / Phase 2 | terminated | Nov 14, 2008 | PrECOG, LLC. | Slow enrollment | Enrollment / accrual |
| NCT00958074 | Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma | Phase 2 | terminated | Aug 13, 2009 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT01676961 | Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving… | Phase 2 | terminated | Aug 31, 2012 | NYU Langone Health | PI left the institution | Investigator |
| NCT02075021 | Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel…(rev/abraxane) | Phase 1 / Phase 2 | terminated | Mar 3, 2014 | NYU Langone Health | PI left the institution | Investigator |
| NCT00809341 | R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's… | Phase 2 | terminated | Dec 17, 2008 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Low accrual | Enrollment / accrual |
| NCT00413959 | VELCADE,Rituximab,Cyclophosphamide and Decadron(VRCD) | Phase 2 | terminated | Dec 20, 2006 | Oncology Specialists, S.C. | not stated | Not stated |
| NCT02602067 | 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients(Tenatumomab) | Phase 1 | terminated | Nov 11, 2015 | sigma-tau i.f.r. S.p.A. | Uptake of drug into the tumour lesion was negligible | Other (stated, no rule matched) |
| NCT01663571 | STAT3 in T Cells: At The Crossroads of Inflammation and Cancer | — | terminated | Aug 13, 2012 | NYU Langone Health | Study is permanently closed to enrollment .Collection of private identifiable information is… | Enrollment / accrual |
| NCT01672736 | A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed… | Phase 1 / Phase 2 | terminated | Aug 27, 2012 | University Health Network, Toronto | The Sponsor decided to stop further manufacture the study drug 'Linsitinib' in Nov 2015. | Drug supply |
| NCT02462525 | Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed… | Phase 1 | terminated | Jun 4, 2015 | AbbVie | No Go decision for ABBV-838 | Other (stated, no rule matched) |
| NCT03212807 | Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS…(DuRIANS) | Phase 2 | withdrawn | Jul 11, 2017 | Singapore General Hospital | FDA Hold for Combination Studies using Imids and PD1/PDL1 Compounds | Other (stated, no rule matched) |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic… | Phase 1 | terminated | Apr 5, 2016 | Stanford University | Accrual factor | Enrollment / accrual |
| NCT02489500 | Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib(VelRand) | Phase 3 | terminated | Jul 3, 2015 | Boston Medical Center | Enrollment held for toxicity evaluation; then closed due to competing trial | Safety / toxicity |
| NCT00918463 | A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With… | Phase 2 | terminated | Jun 11, 2009 | Weill Medical College of Cornell University | The study was terminated early due to lack of accrual. | Enrollment / accrual |
| NCT02228512 | Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated… | Phase 1 / Phase 2 | withdrawn | Aug 29, 2014 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00946023 | Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With… | Phase 2 | terminated | Jul 24, 2009 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Funding was unavailable to complete the study as originally planned. | Funding |
| NCT00847223 | Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell… | Phase 2 | terminated | Feb 19, 2009 | Lymphoma Study Association | Inefficiency of treatment | Other (stated, no rule matched) |
| NCT02030483 | Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma(PD + RD) | Phase 1 | terminated | Jan 8, 2014 | Weill Medical College of Cornell University | The company providing one of the study drugs withdrew its support due to low enrollment. Therefore,… | Enrollment / accrual |
| NCT02986451 | Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma | Phase 2 | withdrawn | Dec 8, 2016 | Sun Yat-sen University | not stated | Not stated |
| NCT03227432 | An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and… | Phase 2 | withdrawn | Jul 24, 2017 | Dana-Farber Cancer Institute | Withdrawn before enrollment due to issues around the FDA hold on PD-1/PD-L1 drugs in combination… | Enrollment / accrual |
| NCT02702141 | A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma | Phase 1 | terminated | Mar 8, 2016 | Seagen Inc. | not stated | Not stated |
| NCT00012298 | Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and… | Phase 1 / Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Trial completed prematurely. | Other (stated, no rule matched) |
| NCT00124579 | S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or… | Phase 2 | terminated | Jul 28, 2005 | SWOG Cancer Research Network | poor accrual | Enrollment / accrual |
| NCT01598025 | Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an… | N/A | terminated | May 15, 2012 | Memorial Sloan Kettering Cancer Center | Closed due to poor accrual | Enrollment / accrual |
| NCT02720510 | A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible,…(PANORAMA4) | Phase 2 | terminated | Mar 28, 2016 | Novartis Pharmaceuticals | A study was terminated due to low enrollment. | Enrollment / accrual |
| NCT01761682 | Acute Lymphoblastic Leukemia Registry at Asan Medical Center | — | terminated | Jan 7, 2013 | Asan Medical Center | The PI resigned the institute, and the rest investigators at the institute decided to terminate the… | Other (stated, no rule matched) |
| NCT01745913 | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood… | Phase 2 | terminated | Dec 10, 2012 | Weill Medical College of Cornell University | Slow accrual | Enrollment / accrual |
| NCT01779167 | Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom…(THRiL for WM) | Phase 2 | terminated | Jan 30, 2013 | Weill Medical College of Cornell University | Slow Accrual | Enrollment / accrual |
| NCT01484626 | Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma(BVRD) | Phase 1 / Phase 2 | terminated | Dec 2, 2011 | Loyola University | Celgene would no longer supply lenalidomide for the study | Drug supply |
| NCT01910428 | L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult… | Phase 1 | terminated | Jul 29, 2013 | ERYtech Pharma | Sponsor decision based off site/PI feedback about | Sponsor / business decision |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or… | Phase 1 | terminated | Jun 20, 2014 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Dec 27, 2018source: clinicaltrials